The application of adjuvant autologous antravesical macrophage cell therapy vs. BCG in non-muscle invasive bladder cancer: A multicenter, randomized trial

Journal of Translational Medicine

Volumn 8, Issue , 2010, Pages

  Burger, Maximilian ^a   Thiounn, Nicolas ^b   Denzinger, Stefan ^a   Kondas, Jozsef ^c   Benoit, Gerard ^d   Chapado, Manuel S ^e   Jimenz Cruz, Fernando J ^f   Kisbenedek, Laszlo ^c   Szabo, Zoltán ^g   Zsolt, Domján ^g   Grimm, Marc O ^h   Romics, Imre ⁱ   Thüroff, Joachim W ^j   Kiss, Tamas ^c   Tombal, Bertrand ^k   Wirth, Manfred ^h   Munsell, Marc ^l   Mills, Bonnie ^m   Koh, Tung ^m   Sherman, Jeff ⁿ  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c Urologiai Sebeszeti Osztaly   (Hungary)

^d BICÊTRE HOSPITAL   (France)

^e HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^f HOSPITAL UNIVERSITARIO LA FE   (Spain)

^g Fövárosi Önkormányzat Jahn Ferenc Dél Pesti ^*  (Hungary)

^h DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

ⁱ SEMMELWEIS UNIVERSITY   (Hungary)

^j JOHANNES GUTENBERG UNIVERSITY   (Germany)

^k CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^l UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^m Inspiration Biopharmaceuticals   (United States)

ⁿ HorizonTherapeutics   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; IMMUNOLOGICAL ADJUVANT;

ADULT; AGED; APHERESIS; ARTICLE; BLADDER CANCER; CANCER INVASION; CANCER STAGING; CELL THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSURIA; EX VIVO STUDY; FEMALE; FEVER; HEMATURIA; HUMAN; IMMUNE RESPONSE; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; POLLAKISURIA; RANDOMIZED CONTROLLED TRIAL; TRANSURETHRAL RESECTION; TREATMENT RESPONSE; URINARY TRACT INFECTION; BLADDER TUMOR; COMPARATIVE STUDY; DEMOGRAPHY; IMMUNOLOGY; IMMUNOTHERAPY; MICROBIOLOGY; MIDDLE AGED; MUSCLE; MYCOBACTERIUM BOVIS; PATHOLOGY; TRANSPLANTATION;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; AGED, 80 AND OVER; DEMOGRAPHY; FEMALE; HUMANS; IMMUNOTHERAPY; MACROPHAGES; MALE; MIDDLE AGED; MUSCLES; MYCOBACTERIUM BOVIS; NEOPLASM INVASIVENESS; URINARY BLADDER NEOPLASMS;

EID: 77953125634     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-8-54     Document Type: Article

References (30)

1. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J. EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder. Eur Urol 2008, 54(2):303-14. 10.1016/j.eururo.2008.04.051, 18468779.
2. Witjes JA, Hendricksen K. Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results. Eur Urol 2008, 53(1):45-52. 10.1016/j.eururo.2007.08.015, 17719169.
3. Herr HW, Morales A. History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. J Urol 2008, 179(1):53-6. 10.1016/j.juro.2007.08.122, 17997439.
4. Ojea A, Nogueira JL, Solsona E, Flores N, Gómez JM, Molina JR, Chantada V, Camacho JE, Piñeiro LM, Rodríguez RH, Isorna S, Blas M, Martínez-Piñeiro JA, Madero R, . CUETO Group (Club Urológico Español De Tratamiento Oncológico) A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. Eur Urol 2007, 52(5):1398-406. 10.1016/j.eururo.2007.04.062, 17485161, CUETO Group (Club Urológico Español De Tratamiento Oncológico).
5. Fernandez-Gomez J, Solsona E, Unda M, Martinez-Piñeiro L, Gonzalez M, Hernandez R, Madero R, Ojea A, Pertusa C, Rodriguez-Molina J, Camacho JE, Isorna S, Rabadan M, Astobieta A, Montesinos M, Muntañola P, Gimeno A, Blas M, Martinez-Piñeiro JA, . Club Urológico Español de Tratamiento Oncológico (CUETO) Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials. Eur Urol 2008, 53(5):992-1001. 10.1016/j.eururo.2007.10.006, 17950987, Club Urológico Español de Tratamiento Oncológico (CUETO).
6. Sylvester RJ. Editorial comment on: prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials. Eur Urol 2008, 53(5):1002. 10.1016/j.eururo.2007.10.007, 17950990.
7. Denzinger S, Fritsche HM, Otto W, Blana A, Wieland WF, Burger M. Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach?. Eur Urol 2008, 53(1):146-52. 10.1016/j.eururo.2007.06.030, 17624657.
8. Witjes JA. Management of BCG failures in superficial bladder cancer: a review. Eur Urol 2006, 49(5):790-7. 10.1016/j.eururo.2006.01.017, 16464532.
9. Herr HW. Is maintenance Bacillus Calmette-Guérin really necessary?. Eur Urol 2008, 54(5):971-3. 10.1016/j.eururo.2008.06.062, 18585842.
10. Zlotta AR, Van Vooren JP, Denis O, Drowart A, Daffé M, Lefèvre P, Schandene L, De Cock M, De Bruyn J, Vandenbussche P, Jurion F, Palfliet K, Simon J, Schulman CC, Content J, Huygen K. What are the immunologically active components of bacille Calmette-Guérin in therapy of superficial bladder cancer?. Int J Cancer 2000, 87(6):844-52. 10.1002/1097-0215(20000915)87:6<844::AID-IJC14>3.0.CO;2-5, 10956396.
11. Luo Y, Yamada H, Evanoff DP, Chen X. Role of Th1-stimulating cytokines in bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against mouse bladder cancer MBT-2 cells. Clin Exp Immunol 2006, 146(1):181-8. 10.1111/j.1365-2249.2006.03191.x, 1809722, 16968412.
12. Ayari C, LaRue H, Hovington H, Decobert M, Harel F, Bergeron A, Têtu B, Lacombe L, Fradet Y. Bladder tumour infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy. Eur Urol 2009, 55(6):1386-95. 10.1016/j.eururo.2009.01.040, 19193487.
13. de Reijke TM. Editorial comment on: Bladder tumour infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy. Eur Urol 2009, 55(6):1395-6. 10.1016/j.eururo.2009.01.041, 19193488.
14. Takayama H, Nishimura K, Tsujimura A, Nakai Y, Nakayama M, Aozasa K, Okuyama A, Nonomura N. Increased infiltration of tumour associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation. J Urol 2009, 181(4):1894-900. 10.1016/j.juro.2008.11.090, 19237175.
15. Brandau S. Tumour associated macrophages: predicting bacillus Calmette-Guerin immunotherapy outcomes. J Urol 2009, 181(4):1532-3. 10.1016/j.juro.2009.01.066, 19230928.
16. Siracusano S, Vita F, Abbate R, Ciciliato S, Borelli V, Bernabei M, Zabucchi G. The role of granulocytes following intravesical BCG prophylaxis. Eur Urol 2007, 51(6):1589-97. 10.1016/j.eururo.2006.11.045, 17222501.
17. Brandau S, Suttmann H, Siracusano S, Vita F, Abbate R, Ciciliato S, Borelli V, Bernabei M, Zabucchi G. The role of granulocytes following intravesical BCG prophylaxis. Eur Urol 2007, 51:1589-99. Eur Urol 2007, 52(4):1266-7, 10.1016/j.eururo.2006.11.045, 17222501.
18. Suttmann H, Jacobsen M, Reiss K, Jocham D, Böhle A, Brandau S. Mechanisms of bacillus Calmette-Guerin mediated natural killer cell activation. J Urol 2004, 172(4 Pt 1):1490-5. 10.1097/01.ju.0000131944.52354.63, 15371877.
19. Pagès F, Lebel-Binay S, Vieillefond A, Deneux L, Cambillau M, Soubrane O, Debré B, Tardy D, Lemonne JL, Abastado JP, Fridman WH, Thiounn N. Local immunostimulation induced by intravesical administration of autologous interferon-gamma-activated macrophages in patients with superficial bladder cancer. Clin Exp Immunol 2002, 127:303-309. 10.1046/j.1365-2249.2002.01766.x, 1906328, 11876754.
20. Brandau S, Suttmann H, Riemensberger J, Seitzer U, Arnold J, Durek C, Jocham D, Flad HD, Böhle A. Perforin-mediated lysis of tumor cells by Mycobacterium bovis Bacillus Calmette-Guérin-activated killer cells. Clin Cancer Res 2000, 6(9):3729-38.
21. Cheadle EJ, Selby PJ, Jackson AM. Mycobacterium bovis bacillus Calmette-Guérin-infected dendritic cells potently activate autologous T cells via a B7 and interleukin-12-dependent mechanism. Immunology 2003, 108(1):79-88. 10.1046/j.1365-2567.2003.01543.x, 1782863, 12519306.
22. Atkins H, Davies BR, Kirby JA, Kelly JD. Polarisation of a T-helper cell immune response by activation of dendritic cells with CpG-containing oligonucleotides: a potential therapeutic regime for bladder cancer immunotherapy. Br J Cancer 2003, 89(12):2312-9. 10.1038/sj.bjc.6601474, 2395264, 14676812.
23. Chokri M, Lopez M, Oleron C, Girard A, Martinache C, Canepa S, Siffert JC, Bartholeyns J. Production of human macrophages with potent antitumour properties (MAK) by culture of monocytes in the presence of GM-CSF and 1,25-dihydroxy vitamin D3. Anticancer Res 1992, 12:2257-2260.
24. Monnet I, Breau JL, Moro D, Lena H, Eymard JC, Ménard O, Vuillez JP, Chokri M, Romet-Lemonne JL, Lopez M. Intrapleural infusion of activated macrophages and gamma-interferon in malignant pleural mesothelioma: a phase II study. Chest 2002, 121:1921-1927. 10.1378/chest.121.6.1921, 12065358.
25. de Gramont A, Gangji D, Louvet C, Garcia ML, Tardy D, Romet-Lemonne JL. Adoptive immunotherapy of ovarian carcinoma. Gynecol Oncol 2002, 86:102-103.
26. Thiounn N, Pages F, Mejean A, Descotes JL, Fridman WH, Romet-Lemonne JL. Adoptive immunotherapy for superficial bladder cancer with autologous macrophage activated killer cells. J Urol 2002, 168(6):2373-6. 10.1016/S0022-5347(05)64148-1, 12441920.
27. Sobin LH, Wittekind C. TNM classification of malignant tumours. 2002, New York, Wiley-Liss, Weinheim, 6.
28. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998, 22(12):1435-48. 10.1097/00000478-199812000-00001, 9850170.
29. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Algaba F, Vicente-Rodriguez J. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 2000, 164:680-684. 10.1016/S0022-5347(05)67280-1, 10954628.
30. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006, 49:466-475. 10.1016/j.eururo.2005.12.031, 16442208.